search
Back to results

MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan
Valsartan
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of ≥ 95 mm Hg and ≤ 114 mm Hg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP)
  • Mean seated systolic blood pressure ≥ 140 mm Hg and ≤ 200 mm Hg, measured by manual cuff at Visit 6 (baseline BP)
  • A 24-hour mean ABPM measurement of ≥ 130/85 mm Hg evaluated at Visit 7 (baseline ABPM)
  • Age 18 or older
  • Ability to provide written informed consent

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening):

    • Who are not surgically sterile (hysterectomy, tubal ligation)
    • Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include IUD (intrauterine device), oral, implantable or injectable contraceptives
  • Any woman:

    • Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 7)
    • Who is nursing
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters

    • SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
    • Serum creatinine > 2.3 mg/dL
  • At screening (Visit 1): clinically relevant sodium depletion, hyperkalemia, or hypokalemia
  • Known or suspected secondary hypertension
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
  • Congestive heart failure (NYHA (New York Heart Association) functional class CHF (congestive heart failure) III-IV
  • Unstable angina within the past three months
  • Stroke within the past six months
  • Myocardial infarction or cardiac surgery within the past three months
  • PTCA (percutaneous transluminal coronary angioplasty) within the past three months
  • History of angioedema
  • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  • Administration of digoxin or other digitalis-type drugs
  • Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by HbA1C ≥ 10%
  • Known drug or alcohol dependency within the past one year period
  • Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
  • Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 AM
  • Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous MICARDIS® (telmisartan) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
  • Known hypersensitivity to any component of the formulations
  • Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Telmisartan

    Valsartan

    Arm Description

    Outcomes

    Primary Outcome Measures

    Changes from baseline in diastolic and systolic blood pressure during the last 6 hours of a 24-hour dosing interval measured by ambulatory blood pressure monitoring (ABPM)

    Secondary Outcome Measures

    Changes from baseline in diastolic and systolic blood pressures during other times during 24-hr ABPM profile
    Changes from baseline in seated trough diastolic and systolic blood pressures as measured by manual cuff sphygmomanometer
    Blood pressure responder rates based on ABPM
    24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
    Blood pressure responder rates based manual cuff measurements
    24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
    Number of patients with adverse events

    Full Information

    First Posted
    June 26, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02177396
    Brief Title
    MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
    Official Title
    A Prospective Randomized Open-Label Blinded End Point (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Valsartan (80 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    April 1998 (undefined)
    Primary Completion Date
    December 1998 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    The primary aim of the trial was to compare the effect of telmisartan and valsartan in lowering ambulatory diastolic and/or systolic blood pressure in the last six hours of the dosing interval. Secondary variables included changes from baseline in diastolic and systolic blood pressures during other times during the 24-hour ABPM profile, changes from baseline in seated trough diastolic and systolic blood pressures as measured by manual cuff, and responder rates. Assessment of safety was also considered. Adverse events and use of concomitant therapies were monitored at each study visit. Blood pressure and heart rate were collected at each visit. Physical examination, electrocardiograms (ECG) and laboratory tests were completed during the trial as well.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    426 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Telmisartan
    Arm Type
    Experimental
    Arm Title
    Valsartan
    Arm Type
    Active Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    Valsartan
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Changes from baseline in diastolic and systolic blood pressure during the last 6 hours of a 24-hour dosing interval measured by ambulatory blood pressure monitoring (ABPM)
    Time Frame
    Day 1 and 56 of the open-label period
    Secondary Outcome Measure Information:
    Title
    Changes from baseline in diastolic and systolic blood pressures during other times during 24-hr ABPM profile
    Time Frame
    Day 1 and 56 of the open-label period
    Title
    Changes from baseline in seated trough diastolic and systolic blood pressures as measured by manual cuff sphygmomanometer
    Time Frame
    Baseline (day 27 of the single-blind period), days 1, 14, 28, 56 and 57 of the open-label period
    Title
    Blood pressure responder rates based on ABPM
    Description
    24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
    Time Frame
    day 56 of the open-label period
    Title
    Blood pressure responder rates based manual cuff measurements
    Description
    24-hour-mean diastolic blood pressure <= 80 mmHg and/or reduction from baseline of at least 10 mmHg or reduction from baseline in 24-hour-mean systolic blood pressure of at least 10 mmHg
    Time Frame
    days 14, 28, 56 and 57 of the open-label period
    Title
    Number of patients with adverse events
    Time Frame
    up to 57 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Mild to moderate hypertension defined as mean seated diastolic blood pressure measurement of ≥ 95 mm Hg and ≤ 114 mm Hg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP) Mean seated systolic blood pressure ≥ 140 mm Hg and ≤ 200 mm Hg, measured by manual cuff at Visit 6 (baseline BP) A 24-hour mean ABPM measurement of ≥ 130/85 mm Hg evaluated at Visit 7 (baseline ABPM) Age 18 or older Ability to provide written informed consent Exclusion Criteria: Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening): Who are not surgically sterile (hysterectomy, tubal ligation) Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include IUD (intrauterine device), oral, implantable or injectable contraceptives Any woman: Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 7) Who is nursing Hepatic and/or renal dysfunction as defined by the following laboratory parameters SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal Serum creatinine > 2.3 mg/dL At screening (Visit 1): clinically relevant sodium depletion, hyperkalemia, or hypokalemia Known or suspected secondary hypertension Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney Congestive heart failure (NYHA (New York Heart Association) functional class CHF (congestive heart failure) III-IV Unstable angina within the past three months Stroke within the past six months Myocardial infarction or cardiac surgery within the past three months PTCA (percutaneous transluminal coronary angioplasty) within the past three months History of angioedema Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve Administration of digoxin or other digitalis-type drugs Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by HbA1C ≥ 10% Known drug or alcohol dependency within the past one year period Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 AM Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous MICARDIS® (telmisartan) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study Known hypersensitivity to any component of the formulations Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.256_U99-3162.pdf
    Description
    Related Info

    Learn more about this trial

    MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring

    We'll reach out to this number within 24 hrs